KRAS and neoplasm: Some biomarkers, such as the PD‐L1 expression, tumor‐infiltration lymphocytes (TILs), TP53, and KRAS mutation status and tumor mutation burden (TMB), were reported for their predictive value for clinical responses in ICIs therapy.15, 16, 17